Marco Meglio, Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
Dose-Dependent Association Identified Between Parkinson Disease and Physical Activity
November 4th 2021Performing physical activity after receiving a diagnosis of Parkinson disease was associated with a decreased mortality rate, even in individuals with PD who were physically inactive before diagnosis.
NeuroVoices: Le Hua, MD, on Siponimod’s Efficacy Regardless of Age
November 3rd 2021The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health provided context on the EXPAND study, which evaluated treatment efficacy and safety in older and younger patients on siponimod (Mayzent; Novartis).
Post-Hypothermia Rewarming Period Associated With Worse Outcomes in Neonatal Encephalopathy
November 1st 2021An abnormal composite outcome of death or disability at age 18 to 22 months was found in 46% of those who had seizures during rewarming compared with 25% of those without seizures at rewarming.
Bone Marrow-Derived Mesenchymal Stem Cells Show Safety in ALS
October 29th 2021ALSFRS-R and FVC values were stable after cell therapy during the 3-month follow-up; however, the scores and values significantly decreased after 6 months of treatment. The data, the authors noted, warrant future assessments in ALS.
Clinical Characteristic Insights in Myasthenia Gravis Reveal Treatment Insufficiencies
October 20th 2021Investigators found that women with early-onset myasthenia gravis display distinct clinical features in contrast with men with the same condition, who are more like patients with late-onset MG of both sexes.
Eculizumab Shows Better Prolonging of Time to NMOSD Relapse Than Other Treatments
October 17th 2021An indirect comparison study evaluated relative treatment effects of eculizumab (Soliris; Alexion), inebilizumab (Uplizna; Horizon), and satralizumab (Enspryng; Genentech), the 3 FDA-approved options for NMOSD.